Vertex Pharmaceuticals reported third‑quarter 2025 earnings on November 3, 2025, with total revenue of $3.08 billion, up 11% from the same period in 2024. Adjusted earnings per share were $4.80, surpassing consensus estimates of $4.55–$4.57.
Revenue growth was driven by strong sales of cystic fibrosis therapies Trikafta and Kaftrio, which together generated $2.45 billion in the quarter. New product launches also contributed: CASGEVY, a gene‑editing therapy for sickle cell disease and transfusion‑dependent beta‑thalassemia, generated $17 million, while JOURNAVX, a non‑opioid pain medication approved in January 2025, added $20 million.
Vertex raised its full‑year 2025 revenue guidance to $11.9 billion–$12.0 billion, an increase from the prior $11.85 billion–$12.0 billion range. The company also revised its combined non‑GAAP operating‑expense guidance to $5.0 billion–$5.1 billion, reflecting higher investment in research and development and commercialization of its new products.
The company’s cash position remained strong, with $12.0 billion in cash, cash equivalents, and marketable securities as of September 30, 2025. Vertex continues to expand its portfolio beyond cystic fibrosis, with ongoing progress in kidney disease and type 1 diabetes programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.